Gain-of-Function Research and the COVID Origins Debate

Gain-of-Function Research and the COVID Origins Debate
Above: Health workers conduct COVID-19 tests at the St. Vincents Hospital drive-through testing clinic at Bondi Beach in Sydney, Australia on June 27, 2021. Image copyright: Steven Saphore/Contributor/AFP via Getty Images

WIV and EcoHealth Alliance Concerns

Concerns about transparency and safety at the WIV were amplified by whistleblower reports and retrospective scrutiny.

In late 2019, Chinese physician Dr. Li Wenliang raised early warnings about a novel virus, which were subsequently suppressed by local authorities. In 2020, reports emerged suggesting that several scientists who publicly dismissed the lab-origin hypothesis had undisclosed ties to WIV research, raising questions about potential conflicts of interest.

Above: The Wuhan Institute of Virology in Wuhan, China on Feb. 3, 2021, Image copyright:Hector Retamal/AFP/Getty Images

EcoHealth Alliance and GOF Research Partnerships

Additional attention focused on the role of EcoHealth Alliance, a U.S. organization that facilitated international research partnerships, including collaborations between the WIV and Dr. Ralph Baric’s lab at the University of North Carolina.

By 2018, EcoHealth Alliance received up to $15 million annually from various U.S. government agencies, some of which flowed to the WIV. Dr. Shi Zhengli's records indicate that between 2014 and 2019, the WIV received over $1.2 million in U.S. grants.

Meanwhile, critics argued that GOF studies on coronaviruses were conducted at the WIV in collaboration with Baric's lab. Some researchers contended that studies involving the insertion of human-pathogenic spike proteins into viral backbones from 2017 to 2019 qualified as GOF work, while others disagreed, noting the experiments may not have met the NIH’s technical definition.

The NIAID continued to approve experiments at the WIV despite the 2014 DHHS moratorium on GOF research.

Above: Former NIAID Director Dr. Anthony Fauci testifies before the House Select Committee on the Coronavirus, Washington, D.C. on June 3, 2024, Image copyright:Allison Bailey/Middle East Images/AFP/Getty Images

Reassessment of WIV Laboratory Safety

Long-standing safety concerns about the WIV were also revisited. France warned U.S. officials about inadequate safety protocols at the lab, while in 2018, U.S. embassy officials raised alarms about safety protocols at the WIV, noting the institute's inexperience in operating high-containment laboratories. The lab's location in a densely populated area was also criticized as unsuitable for high-risk research.

Multiple safety audits reportedly revealed lapses without subsequent corrective action. Some reports alleged that certain experiments were conducted under BSL-2 (biosafety level 2) conditions rather than the more secure BSL-4, despite internal and external warnings.